Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

This study tests a new medicine called HDM1005 in people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. About 240 adults will receive either HDM1005 or a placebo for up to 52 weeks. The main goal is to see if HDM1005 safely lowers blood …

This early-phase study tests a new drug called HDP-101 in 15 Chinese patients with multiple myeloma, a type of blood cancer. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can control the cancer.

This study tests a new cream called MC2-01 for plaque psoriasis, a skin condition causing red, scaly patches. About 537 adults in China will use the cream daily for 8 weeks to see if it clears skin better than a standard gel or a placebo. The goal is to find a safe and effective …

This early-phase study tests an experimental drug called HDM2006 in 48 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug…

This study tests whether a combination of three diabetes drugs (metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist) works better than other oral medications for people with type 2 diabetes who have poor blood sugar control. About 430 adults aged 18-75 with a BMI of 20 or hig…

This early-stage trial tests a new drug called HDM2024 in about 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to find the best dose. Participants receive the drug once every three weeks, wi…

This study tests a new weekly injection called HDM1005 against the existing drug tirzepatide for weight loss in 372 adults with obesity (BMI 28-40) who do not have diabetes. Participants receive either HDM1005 or tirzepatide for 52 weeks, plus diet and exercise counseling. The ma…

This study tests a new medicine called HDM1005, given as a weekly injection, to help people with obesity or overweight lose weight. About 825 Chinese adults who do not have diabetes will receive either the drug or a placebo for 52 weeks, along with diet and exercise advice. The m…

This early-phase study tests a new drug called HDM2017 in about 96 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug a…

This study tests a new tablet called HDM1002 in 360 adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. Participants will take either the study drug or a placebo for 40 weeks to see if it safely lowers blood sugar levels. The goal is t…

This study tests an experimental drug called HDM1005 to help obese adults who do not have diabetes lose weight. About 240 people will receive either the drug or a placebo injection. The main goal is to see how much weight they lose after 22 weeks, and whether the drug is safe.

This study checks whether a single dose of HDM1002 tablets changes the heart's electrical activity in 72 healthy adults aged 18 to 45. Participants receive the drug, a placebo, and an active control in random order. The goal is to measure any effects on heart rhythm, not to treat…

This early-stage study is looking at how a new drug called HDM1002 interacts with five common medications (metformin, empagliflozin, midazolam, valsartan, and warfarin) in overweight or obese adults. The goal is to see if taking them together changes drug levels in the body and t…